ALBERT DAVID LTD-$
Add to watch list to get report alerts
BSE Code:
524075
NSE Code:
ALBERTDA
Business Profile
Business Profile
Incorporated in 1938, Kolkata-based Albert David (ADL) is a part of Kothari group. The company manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles. ADL operates in the therapeutic segments of anti-biotics, anti-ulcerants, analgesics, anti-inflammatory, antipyretics, dermatologicals and anti cough preparations. The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its product under brand names like Adliv, which is a hepato protective and Siotone capsule which is the only adaptogen indicated for stress. ADL exports its products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, the Netherlands and Germany. ADL has tie-ups with Ajinomoto Co. and Roussel Morishita Co. of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India. Manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.
Financials
The company reported a 6.58% decline in net profits at Rs 33.48 million for the quarter ended Sep. 2006 as against Rs 35.84 million during the corresponding quarter in the previous year. Sales for this period had increased 16.82% to Rs 380.17 million from Rs 325.43 million. ADL, for the year ended Mar. 2006, had reported a 13.73% increase in sales to Rs 1,168.09 million as against Rs 1,027.07 million for the year ended Mar. 2005. Net profit for this period had also increased 76.39% to Rs 74.17 million as against Rs 42.05 million. The EPS for FY06 stood at Rs 13.
Future Plans
The company will explore the possibilities for export of its IV Fluids, small volume parenterals and disposable syringes in addition to their existing range. It will concentrate on product line extension for their flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage. Future expansion in the herbal product range will be focused in the area of women`s healthcare. ADL is planning to enter newer therapeutic areas like dermatological and opthalmological segments. Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management. The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.